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Abstract 
Sulfamethazine (SMT) is a sulfonamide antibacterial drug used to treat or prevent 
infections in both humans and animals.  However, SMT has an unfavorable taste 
and poor compaction behavior.  To overcome these problems, a 1:1 complex with 
an artificial sweetener, acesulfame (Acs), was prepared and characterized.  The 
single crystal structure suggests that the new complex, SMT-Acs, is a salt.  This 
was confirmed by analysis of C-N bond length and comparison to multicomponent 
SMT crystals with known ionization states of SMT and Fourier transformation 
infrared spectroscopy.  The applicability of the ΔpKa rule in multicomponent 
crystals of SMT is discussed.  SMT-Acs exhibits better tabletability than SMT, 
which is attributed to its greater plasticity as shown by Heckel and Kuentz – 
Leuenberger analysis.  The greater plasticity of SMT-Acs is consistent with the 
presence of slip planes identified by combined energy framework and topological 
analysis of the crystal structure. 
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1.1 General Introduction 
The tablet is the most commonly used dosage form for oral drug delivery.
1
  It has 
advantages over other dosage forms, including 1) accurate dose; 2) generally better 
chemical, physical and microbiological stability; 3) lower cost for manufacturing 
and distribution; 4) ease of administration; and 5) better patient compliance.
2-4
  In 
order to develop a successful tablet product, several quality standards have to be met 
to ensure the efficacy and safety of the drug product.  Adequate tablet mechanical 
strength is one of the key factors that needs to be considered.
5
 
Crystal engineering is the rational design of fundamental molecular solids.
6
  It is of 
both fundamental and practical interest to scientists in multiple fields, such as 
chemistry, material science, and pharmaceutical sciences.
7
  Specifically in 
pharmaceutical sciences, crystal engineering has gradually become a successful 
design strategy to obtain novel multicomponent complexes of active pharmaceutical 
ingredients (APIs) with desired physicochemical properties but without affecting 
their pharmacological performances.
8
  Numerous recent examples have amply 
shown the applicability of crystal engineering in improving mechanical properties, 
stability, solubility, and bioavailability of APIs.
9-12
 
Understanding the relationship between crystal packing and the mechanical 
properties of the crystals is of interest in the fields of solid-state chemistry and 
crystal engineering.
9, 10, 12, 13
  In pharmaceutical sciences, the structure-property 
relationship provides a foundation for understanding different tableting behaviors of 
 
 
3 
 
APIs.
12, 14-16
 Pursuit of greater applicability of this relationship is now aided by 
computational tools, such as energy framework calculation and topology analysis, 
which can bring the goal of accurately predicting the compaction behaviors of 
crystals closer.
17, 18
 
1.2 The Tablet 
The tablet originated in mid 1800s and has been extensively investigated and widely 
used for many APIs.
19
  Based on the intended clinical use, several types of tablets 
have been designed, including: 1) immediate release; 2) sustained/controlled release; 
3) delayed release; 4) buccal and sublingual; 5) chewable; 6) effervescent, and 7) 
orally disintegrating tablets.
2
  A tablet product may belong to more than one of the 
specific types. 
Tablets exhibit advantages in both manufacturing and administration.  With respect 
to manufacturing, tablets generally exhibit better chemical, physical and 
microbiological stability, lower cost for manufacturing and distribution, as well as 
more accurate dose.
2-4
  The ease of administration is another major benefit that 
leads to better patient compliance and therapeutic outcomes.
2-4
 
In order to develop a successful tablet product, several quality standards have to be 
met to ensure efficacy and safety.  Adequate mechanical strength is essential as a 
tablet cannot exist in its absence.
5
  Parameters, such as particle size and shape, 
surface texture, plasticity, brittleness, viscoelasticity, and moisture content, can all 
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influence the tableting behavior of APIs. 
1.2.1 Tablet compaction 
Tablets are typically prepared with a tablet press, where the volume of a powder is 
reduced under a compaction force.
20
  The compaction process, which takes place in 
a tooling set (a die and two punches), can be divided into four phases involving the 
specific mechanisms of 1) die filling and particle slippage, 2) compression, 3) 
decompression and 4) ejection.
21, 22
  When the punches come in contact with the 
powder in the die, a low pressure is applied and particles undergo rearrangement 
through sliding and rotation. This results in a more densely pack powder bed in the 
die.  Displacement of trapped air in bulk powder occurs, and the powder bed 
porosity decreases.  At a critical porosity, the loose powder transitions into a rigid 
body,
22
  marking the initiation of the compression stage.  The continuously 
increasing compaction pressure and volume reduction of the powder causes 
deformation of the particles, including particle fracture, elastic deformation, and 
plastic deformation. Elastic deformation is temporary and reversible, but plastic 
deformation is permanent and irreversible.
21
  The compaction pressure reaches the 
maximum at the end of the compression phase. The decompression phase, where the 
punches move away from each other, ensures the stress is reduced to zero.  In the 
ejection phase, the compact is pushed out of the die.  Tablets gain their mechanical 
strength from the compaction process, and the mechanical strength is governed by 
the total area of contact (bonding area) and the strength of particle interactions 
 
 
5 
 
(bonding strength).
21
  This bonding area – bonding strength (BABS) interplay 
model will be further discussed in 1.2.3. 
1.2.2 Tablet mechanical strength 
The mechanical strength of tablets obtained is dependent upon a number of factors, 
e.g., physicochemical, particulate and mechanical properties of the bulk powder, as 
well as the conditions used for powder compression, such as compaction pressure 
and speed.
23, 24
  Tablet mechanical strength can be quantified by a number of 
standard measurements, including breaking force 
25
, tensile strength
21
, fracture 
toughness
25
, indentation hardness,
26
 and tablet friability
27
. 
Tablet tensile strength is one of the most commonly used parameter for quantifying 
mechanical strength.
28
  Unlike breaking force, tablet size and geometry are taken 
into account in the determination of tensile strength.  The tensile strength (σ) of a 
cylindrical tablet can be obtained from the diametral compression test
29
, using eqn. 1 
σ =  
2𝐹
𝜋𝐷ℎ
                                                   (1) 
Where F is the breaking force, D is tablet diameter, and h is tablet thickness.   
 
Adequate tablet tensile strength is required for successful tablet product development 
and manufacturing.  On one hand, sufficient strength is needed for tablets to 
maintain their integrity during packaging, shipping and handling.  Weak tablets may 
lead to problems, including unacceptable friability, reduced dose and a lack of 
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pharmaceutical elegance (good quality in tablet size, shape and color).  On the other 
hand, very strong tablets are difficult to break, as may be needed for patients with 
difficulty in swallowing.  Furthermore, it can also result in slower rate of tablet 
disintegration and drug dissolution.
21
 
1.2.3 The bonding area – bonding strength (BABS) model 
Tabletability is the ability of a material to form tablets with adequate mechanical 
strength by powder compaction, which is of critical importance to successful tablet 
product manufacturing.
21
  Tabletability profiles can be obtained by plotting tablet 
tensile strength as a funtion compaction pressure.  To explain the diverse tableting 
behaviors of pharmaceutical powders,15, 30-37  a theoretical framework has been 
developed. 
The BABS model is a qualitative model based on the concept of interparticulate 
boding area (BA) and boding strength (BS).
21
  For molecular solids, van der Waals 
interactions as well as hydrogen bonding are primariy responsible for BS.  During 
the consolidation process, the powder undergoes particle rearrangement, slippage 
and deformation, resulting in formation of BA.  BA varies with mechanical and 
particle properties (e.g., size and shape).  The various combinations of BA and BS lead to 
the diverse tabletability behaviors of pharmaceutical powders, i.e., tabletability is the 
result of the interplay between BA and BS.  A clear understanding of the 
contributions of BA and BS to tensile strength can guide effective formulation and 
process development to overcome problems due to low tabletability.  
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1.3 Crystal Engineering 
Crystal engineering is the rational design of fundamental molecular solids.
6
  It is of 
both fundamental and practical interest to researchers in multiple fields such as 
chemistry, material science, and pharmaceutical sciences.
7
  Today, this subject is 
actively pursued by at least 150 independent research groups worldwide, covering 
topics such as 1) intermolecular interactions; 2)  packing modes, in the context of 
these interactions and with the aim of defining a design strategy; and 3) crystal 
structure - properties relationship and their applications to improve properties 
through crystal structure modifications.
7
 
In pharmaceutical sciences, the crystal engineering approach has progressed to 
become a successful designing strategy to obtain novel multicomponent complexes 
of the APIs exhibiting desired physicochemical properties without affecting their 
pharmacological performances.
8
  Numerous examples in recent times have shown 
its application in attaining desirable mechanical and physicochemical properties, 
such as stability, solubility, and bioavailability.
9-12
  In this line of research, it is of 
fundamental importance to solve the crystal structure of the API, which facilitates 
the understanding of the structure – property relationship.  These information 
augments the Quality by Design (QbD) objective (a systematic approach to 
development that begins with predefined objectives and emphasizes product and 
process understanding and process control, based on sound science and quality risk 
management) of pharmaceuticals in solid state.
38
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1.3.1 The cocrystal - salt continuum and pKa rule 
Both cocrystals and salts have been used to improve pharmaceutical properties of 
APIs.
11, 39-41
  However, cocrystals are not regarded as new pharmaceutical APIs 
whereas salts are.  This means that a complete set of characterization data is 
required for FDA approval of pharmaceutical products containing different salts.
42
  
This regulatory distinction makes it important to identify the ionization state of each 
new multicomponent complex intended for further pharmaceutical development. 
The criterion that distinguishes a cocrystal drug from a salt is proton transfer.  In 
multicomponent crystal systems, the position of the proton between the two 
components can be continuous based on their chemical nature, ranging from 
covalently bonded to the donor molecule to covalently bonded to the acceptor 
molecule.
43, 44
  However, sometimes, it is difficult to apply this seemingly simple 
criterion to identify a cocrystal or salt, because of several phenomena: 1) partial 
proton transfer
45
; 2) position shift of a proton with temperature between the same 
pair of acid and base
46
; 3) the extent of proton transfer depends on the packing 
patterns of molecules in different polymorphs and hydrates
47
. 
The empirical ∆pKa rule, which was developed on the basis of an analysis of 6465 
crystalline complexes, has been used to predict the ionization state of crystalline 
complexes.
48, 49
  A larger ΔpKa is correlated with a higher tendency of proton 
transfer. Generally, when the ΔpKa (= pKa [base] – pKa [acid]) is greater than 3, proton 
transfer is highly likely to occur.
49
  When ΔpKa < 0, proton transfer is unlikely and 
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cocrystal would be expected.  In the cases of ΔpKa between 0 and 3, either salt or 
cocrystal could form.
43
  However, the U.S. FDA proposed ΔpKa = 1 as the 
boundary between cocrystals and salts, i.e., when ΔpKa > 1, substantial proton 
transfer is likely to occur, resulting in salt formation; and when ΔpKa < 1, cocrystals 
are expected to be obtained.
42
 
1.3.2 Impact on drug properties and performance 
Each new multicomponent complex of any drug is expected to exhibit a distinct set 
of properties because of the unique structure.
50
  Thus, forming multicomponent 
complex crystals is an effective strategy for improving manufacturability and 
clinical performance of drug products.  Demonstrated advantages of this strategy 
include: 1) higher solubility, dissolution rate, and bioavailability;
51-54
 2) greater 
physical and chemical stability;
55-57
 3) better mechanical properties;
11, 12, 58
 and 4) 
improved taste profiles.
59-61
 
1.4 Structure – property relationship 
Understanding the relationship between crystal packing and the mechanical properties 
of the crystals is of interest to researchers in the fields of solid – state chemistry and 
crystal engineering.
9, 10, 12, 13
  For example, such structure – property relationships 
help explain the different tableting behavior of the material.
12, 14-16
  In addition, 
computational methods, such as energy framework calculation and topology analysis, 
can be used to further gain insight and possibly predict the compaction behavior of 
 
 
10 
 
different crystals.
17, 18
  Acetaminophen is a good example of the efforts in developing 
the structure – property relationship.  The orthorhombic form II was initially 
observed to exhibit greater tabletability compared with the monoclinic form I.
62
  
Later, an analysis of the crystal structures gave clues to their distinct tableting 
behavior: 1) pleated sheets along b – axis for form I, resulting in relatively stiff 
structure and poor compaction behavior, and 2) parallel hydrogen – bonded sheets 
along c – axis for form II, serving as slip planes to facilitate plastic deformation.63  
More recently, energy framework calculations showed that form II molecule has 
lower intermolecular interaction energy between neighboring sheets (-106 kJ/mol
-1
) 
compared with a form I molecule (-143 kJ/mol
-1
), indicating easier slide between 
sheets for form II than form I.  This explains the greater plasticity and tabletability of 
form II.
64
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Overview 
Sulfamethazine (SMT) is a sulfonamide antibacterial drug used to treat or prevent 
infections in both humans and animals.  However, SMT exhibits unfavorable taste 
and poor compaction behavior.  To overcome these problems, a 1:1 complex with 
an artificial sweetener, acesulfame (Acs), was prepared and characterized.  The 
single crystal structure suggested that the new complex, SMT-Acs, is a salt.  This 
was confirmed by an analysis of C-N bond length in comparison to those of 
multicomponent SMT crystals with known ionization states of SMT and Fourier 
transformation infrared spectroscopy.  The applicability of the ΔpKa rule in 
multicomponent crystals of SMT was discussed.  SMT-Acs exhibits better 
tabletability than SMT, which is attributed to its greater plasticity as shown by 
Heckel and Kuentz – Leuenberger analysis.  The greater plasticity of SMT-Acs is 
consistent with the presence of slip planes identified by combined energy framework 
and topological analysis of the crystal structure. 
 
 
 
2.1 Introduction 
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Crystal engineering, “the rational design of functional molecular solids”, is of interest 
in multiple research fields, including pharmaceutical sciences.
1, 2
  Numerous 
examples have shown the ability of attaining desirable physicochemical and 
mechanical properties (i.e., stability, solubility and bioavailability) of active 
pharmaceutical ingredients (APIs).
3-6
  Salt formation is an effective crystal 
engineering approach, where charge assisted intermolecular interactions play an 
important role in directing molecule packing in crystals.  Hence, salt formation has 
been routinely applied to improve pharmaceutical properties of APIs.
7-9
 
Sulfamethazine (SMT, Scheme 2.1a) is a sulfonamide antibacterial drug, which is 
used to treat or prevent infections in both humans and animals, with a broad spectrum 
of activity against gram-positive bacteria, gram-negative bacteria, and some 
protozoa.
10, 11
  SMT can exist in two neutral tautomers, amidine
11-23
 and imidine, 
11, 17, 
24
  cation (protonation of the -NH2 group, pKa,1 = 2.65),
24-26
 and anion (deprotonation 
of the sulfonamide -NH- group, pKa,2 = 7.65).
16
   Correspondingly, various organic 
salts and pharmaceutical cocrystals of SMT were prepared and characterized with a 
focus on crystal structures and solid – state properties, except for compaction 
properties.  Taste masking and compaction property enhancement of SMT are 
desired for developing high quality oral tablet products.
27
 
Acesulfame (Acs, Scheme 2.1b), a relatively strong acid (pKa = 2.0), is a calorie-free 
sugar substitute that is 200 times sweeter than sucrose.
28
  Because of its safety 
profile,
29
  Acs is a good candidate for masking the bitterness of SMT through 
forming a crystalline complex, as demonstrated in other drugs.
30, 31
  The multiple 
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functional groups (amide and sulfonyl amide) of Acs allows interaction with SMT 
hydrogen donating groups of amine (-NH2) and sulfonamide (-NH-) and accepting 
groups of sulfoxy -O-, amine -N-, and pyrimidine -N-.
11, 32
  In this work, we 
investigated the possibility of forming a sweet SMT-Acs complex to improve the poor 
mechanical properties and taste of SMT.  
 
2.2 Material and methods 
2.2.1 Materials 
Sulfamethazine (Sigma-Aldrich, St. Louis, MO), acesulfame potassium (Tokyo 
Chemical Industry co., Ltd., Japan), and acetonitrile (Sigma-Aldrich, St. Louis, MO) 
were used as received.  Acs free acid was prepared from acesulfame potassium using 
a reported method.
32 
2.2.2 Preparation of single crystals 
Equimolar SMT (556.7 mg, 2 mmoL) and Acs (326.3 mg, 2 mmoL) were suspended 
in 10 mL of acetonitrile.  The suspension was stirred with a magnetic stirring bar for 
24 h at room temperature.  After 24 h, the suspension was filtered through filter 
paper with a Brinell funnel, and the filtrate was collected and passed through a 0.22 
mm PTFE syringe filter membrane into a vial.  The vial was left open in a fume 
hood to allow solvent evaporation.  Crystals suitable for single crystal X-ray 
diffraction study were harvested within one week. 
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2.2.3 Synthesis of SMT-Acs salt bulk powder 
Bulk powders of SMT-Acs salt for compaction study were prepared by suspending 
SMT (5.57 g, 20 mmoL) and Acs (3.26 g, 20 mmoL) in 30 mL of acetonitrile and 
stirred for 24 h at room temperature.  After 24 h, the solid phase was isolated by 
filtration using a Brinell funnel, and the dried at room temperature overnight. 
2.2.4 Single Crystal X-Ray Diffraction (SCXRD) 
SCXRD was conducted on a Bruker-AXS Venture Photon-II diffractometer (Bruker 
AXS Inc., Madison, Wisconsin), with a Photon-II (CMOS) detector.  Data was 
collected at 100 K using Mo Kα radiation (graphite monochromator).  Various 
software packages from Bruker, including APEX3, SADABS, and SAINT, were used 
for data analysis.  The structure was solved using SHELXT 2014 program and 
refined using SHELXL 2018 program.
33, 34
  The space group P21/n was determined 
based on systematic absences and intensity statistics.  A direct-methods solution was 
calculated to provide most non-hydrogen atoms from the E-map.  Full-matrix 
least-squares/difference Fourier cycles were performed to locate the remaining 
non-hydrogen atoms.  All non-hydrogen atoms were refined with anisotropic 
displacement parameters.  All hydrogen atoms were placed in ideal positions and 
refined as riding atoms with relative isotropic displacement parameters. 
2.2.5 Powder X-ray Diffractometry (PXRD) 
PXRD experiments were performed on a powder X-ray diffractometer (PANalytical 
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X’pert pro, Westborough, MA), using Cu Kα radiation (1.54056 Å).  Samples were 
scanned with a step size of 0.02° and 1 s/step dwell time from 5 to 35° two theta.  
The tube voltage and amperage were 45 kV and 40 mA, respectively. 
2.2.6 Thermal Analysis 
Hot stage microscopy (HSM) was carried out using a polarized light microscopy 
(Eclipse e200; Nikon, Tokyo, Japan), fitted with a hot stage.  Images were captured 
by a DS-Fi1 microscope digital camera.  Crystals were heated at a rate of 5 °C/min 
with a temperature controller (Linksys 32; V.2.2.0, Linkam Scientific Instruments, 
Ltd., Waterfield, UK). 
The thermal properties collected on a differential scanning calorimeter (DSC) (Q1000, 
TA Instruments, New Castle, DE, USA).  Powder samples (2~4 mg) were 
hermetically sealed in aluminum pans and heated with a heating rate of 10 °C/min 
under continuous dry nitrogen purge at a flow rate of 25 mL/min.  Thermal 
gravimetric analysis (TGA) data were collected using a thermogravimetry analyzer 
(Model Q500, TA Instruments, New Castle, DE, USA).  Powder samples (3~5mg) 
were loaded in open aluminum pans, and heated from room temperature up to 300 °C 
at 10 °C/min under a continuous dry nitrogen purge at 60 mL/min. 
2.2.7 Fourier Transformation Infrared Spectroscopy (FT-IR) 
FT-IR spectra of all solid samples were obtained using a high resolution FT-IR 
spectrometer (VERTEX 70, Bruker Optics Inc., Billerica, MA. USA).  A total of 32 
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scans for each sample were collected at 4 cm
-1
 resolution, and an averaged spectrum 
ranged from 4000 - 600 cm
-1
 was reported. The spectra were processed using OPUS 
software (v5.5, Bruker Optics Inc., Billerica, MA, USA). 
2.2.8 Dynamic Water Vapor Sorption Isotherm (DVS) 
Water sorption isotherms were determined at 25 °C on an automated vapor sorption 
analyzer (DVS 1000, Surface Measurement Systems Ltd., Alperton, Middlesex, UK), 
with continuous 50 mL/min nitrogen flow.  The RH values were increased from 0% 
to 95% using a step size of 5%.  At each step, the sample was equilibrated until one 
of the two criteria was met, dm/dt ≤0.003% or 6 h equilibration period. 
2.2.9 Tabletability 
Powder compaction studies were conducted on a material testing machine (model 
1485; Zwick/ Roell, Ulm, Germany) at 4 mm/min speed.  To minimize the effect of 
particle size, powder samples were ground in a mortar with a pestle and passed 
through a #60 mesh (≤ 250 μm) sieve before compaction.  Comparable particle sizes 
of SMT and SMT-Acs were confirmed by polarized light microscopy.  Compaction 
was carried out over the pressure range of 20 - 320 MPa using a die and flat-faced 
round punches (8 mm diameter).  A suspension of magnesium stearate in ethanol (5% 
w/v) was applied onto the punch tips and die wall using a brush, and then dried by a 
fan prior to filling the die with powder.  Tablets were left in sealed glass vials at 
room temperature for at least 24 h to allow relaxation.  The diametrical breaking 
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force was determined on a texture analyzer (TA-XT2i; Texture Technologies 
Corporation, Scarsdale, New York).  Tablet tensile strength (σ) was calculated using 
eqn. 1.
35
  
𝜎 =  
2𝐹
𝜋𝐷ℎ
                                                   (1) 
Where F is the breaking force, D is tablet diameter, and h is tablet thickness. 
True density of powder samples was measured by helium pycnometry (Quantachrome 
Instruments, ultrapycnometer 1000e, Boynton Beach, Florida).  Samples (1~2g) 
were accurately weighed and placed into a sample cell.  Measurements were 
repeated to a maximum of 100 or a ＜0.005% coefficient of variation of five 
consecutive measurements was obtained.  The mean of the last five measurements 
was reported as the true density of the sample. 
2.2.10 In-Die Heckel Analysis 
Three tablets (about 200 mg) were prepared at peak compaction pressures of 280, 300 
and 320 MPa at 4 mm/min speed using a material testing machine (model 1485; 
Zwick/ Roell, Ulm, Germany).  The force and nominal strain were exported for 
calculating pressure and porosity (ε), which were analyzed using the Heckel 
equation,
36
 eqn. 2 
-ln (ε) = KP + A                                                (2) 
Where P is the compaction pressure applied, the slope K and y-axis intercept A are 
calculated using the linear portion of the Heckel plot. The mean yield pressure (Py), 
which is the reciprocal of K, is a plasticity parameter of the powder.  A lower Py 
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value suggests higher powder plasticity. 
2.2.11 Out-of-Die Kuentz−Leuenberger (KL) analysis 
The out-of-die pressure – porosity data were analyzed using the Kuentz−Leuenberger 
(KL) method (Eqn. 3).
37
  
  𝑃 =
1
𝐶
[𝜀 − 𝜀𝑐 − 𝜀𝑐𝑙𝑛 (
𝜀
𝜀𝑐
)]                                      (3) 
Here, the parameter 1/C is another parameter for quantifying material plasticity.  
Higher plasticity is indicated by a lower 1/C value.  The KL analysis is superior to 
Heckel analysis in analyzing compressibility data, because the former uses the entire 
set of data whereas the latter only uses data that appears linear over a narrower range 
of compaction pressure.
38
 P is the compaction pressure applied, ε is the porosity of the 
powder, and the critical powder porosity, εc, is a parameter that describes the porosity 
at which the powder starts to gain rigidity or strength.
37
 
2.3 Results and discussion 
2.3.1 Crystal structure 
SMT-Acs complex (CCDC: 1821691) crystallizes in the monoclinic P21/n space 
group with four asymmetric units in unit cell (Z = 4, Figure 2.2a).  Each asymmetric 
unit contains one SMT
+
 cation and one Acs
-
 anion (Z’ = 1).   Key crystallographic 
parameters are summarized in Table 2.1, and hydrogen bonds are shown in Table 2.2.  
Proton transfer occurs between SMT N2 site and Acs sulfonyl amide -NH- group.  
SMT
+
 cation and Acs
-
 anion are connected through two hydrogen bonds, namely, 
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N1-H
…
N
 
-3 and N
 + 
2 -H
…
O1＝C2 (Figure 2.2b).  Each SMT
+
 cation is connected to four 
more SMT
+ 
through N-H
…
O＝S (2.995 Å) and one Acs- through the above mentioned 
N1-H
…
N
 
-3 (2.796 Å) and N
 + 
2 -H
…
O1＝C2, (2.627 Å) hydrogen bonds, forming a R
2 
2 (8) 
heterosynthon (Figure 2.2b).  The Acs
- 
also connects to another SMT
+ 
through 
N-H
…
O＝C (3.015 Å).  SMT+ molecules, linked by N-H…O＝S with bond length 
of 2.995 Å, form a zigzag chain along b-axis (Figure 2.2c). The three-dimensional 
packing pattern of SMT-Acs is shown in Figure 2.2d. 
 
2.3.2 Ionization state analysis 
2.3.2.1 Δ pKa analysis 
An empirical ∆pKa rule has been proposed to predict the ionization state of crystalline 
complexes, which have been tested in 6465 crystalline complexes.
39, 40
  Generally, 
when the ΔpKa (= pKa [base] – pKa [acid]) is greater than 3, proton transfer is highly likely 
to occur since a larger ΔpKa suggests higher tendency of proton transfer.
40
  When 
ΔpKa < 0, proton transfer is unlikely and a cocrystal would be expected.  In the cases 
of ΔpKa between 0 and 3, either salt or cocrystal could form.
41
  On the other hand, 
the U.S. FDA proposed ΔpKa = 1 as the boundary between cocrystals and salts, i.e., 
when ΔpKa > 1, substantial proton transfer is likely to occur, resulting in salt 
formation; and when ΔpKa < 1, cocrystals are expected to be obtained.
42
  . 
A search of CSD returned a total of 32 multicomponent crystals of SMT, including 26 
cocrystals and 6 salts.
43
  Out of the 26 cocrystals, SMT can be present in the form of 
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amidine (19) or imidine (6), with one crystal contains both amidine and imidine forms.  
Out of the 6 salts, 4 are SMT cations and 2 are anions.  However, the application of 
the ΔpKa rule in SMT multicomponent crystals requires caution, since SMT can exist 
in different molecular forms (amidine, imidine, cation, and anion) with different pKas.  
The correct calculation of ΔpKa should consider functional groups that are directly 
involved in the interacting hydrogen/proton donating and accepting groups.  The 
simple use of SMT amine -NH2 group pKa value would have led to an erroneous ΔpKa, 
since the hydrogen/proton donating and accepting groups in many known SMT 
multicomponent structures do not directly involve that group.  By taking account of 
the actual interacting groups, the distribution map of ionization state versus ΔpKa is 
obtained (Figure 2.3, Table 2.3).  Salts could form at ΔpKa well below 0, and 
cocrystals could effectively form at ΔpKa about 3.  A similar result was observed in 
fumaric acid multicomponent crystals recently, in which cocrystals distributed around 
53% in ΔpKa > 0 region and 47% in ΔpKa < 0 region.
44
  Thus, the ΔpKa rule cannot 
be reliably used to predict ionization state in SMT multicomponent crystals.  
Therefore, bond length analysis and infrared spectroscopy were applied to establish 
the ionization state of SMT-Acs. 
2.3.2.2 Bond length analysis 
Bond lengths often give clues to the complex’s ionization state.  Bond length 
diagrams containing different forms of SMT and Acs in known crystal structures are 
shown in Figure 2.4.  For SMT-Acs, the SMT C1-N1
 
and C1-N2 bond lengths (1.366 
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and 1.354 Å, respectively, Figure 2.4a). Thus, SMT-Acs falls into the SMT cation 
region, whereas Acs fall into the anionic group based on C2-N3 and C2-O1 bond 
lengths (1.352 and 1.256 Å, respectively, Figure 2.4b).
32, 45
  Thus, bond length 
analysis indicates salt formation for SMT-Acs. 
2.3.2.3 Fourier Transformation Infrared Spectroscopy 
Characteristic FTIR peaks of SMT and Acs-K can be observed in the spectrum of 
SMT-Acs (Figure 2.5).  For example, the C=O peak (1652 cm
−1
 in Acs-K) shows up 
at 1647 cm
−1
 in SMT-Acs, and the N–H stretching frequency of SMT is shifted from 
3440, 3339 cm
−1
 to 3490 and 3389 cm
−1
 in SMT-Acs.  Additionally, a 2636 cm
−1
 
broad peak is observed in SMT-Acs, which corresponds to the NH
+
 functional group 
stretching (between 2700 and 2400 cm
−1
), confirming that both SMT and Acs are in 
ionic state.
32
  Considering these data, complete proton transfer from Acs to SMT is 
confirmed for SMT-Acs. 
 
2.3.3 Solid-State Characterization 
2.3.3.1 Phase Purity of the Bulk Powders 
Powder X-ray diffractogram (PXRD) of the bulk SMT-Acs powder matched the 
PXRD calculated from the single crystal structure (Figure 2.6). The experimental 
PXRD pattern (room temperature) was shifted to slightly smaller 2θ angles compared 
to the calculated pattern using structure solved at 100 K due to thermal expansion 
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effect.
46, 47
  The good PXRD pattern match confirms the phase purity of the bulk 
powder. 
2.3.3.2 Thermal Analysis 
Both SMT and Acs exhibited single endotherms in their DSC traces (Figure 2.7a), 
with onset temperatures of 197 °C (ΔHf = 144.7 J/g) and 116 °C (ΔHf =130.8 J/g), 
respectively.  Acs is volatile as significant weight loss occurred after melting (Figure 
2.7c).  SMT did not undergo detectable weight loss until about 20 
o
C above melting 
temperature (Figure 2.7c).  An exothermal peak 198 °C was observed in SMT-Acs 
after the endothermal peak.  These thermal events corresponded to bubbling at 
198 °C without any sign of melting (Figure 2.7b), indicating dissociation of SMT and 
Ace and subsequent evaporation of Ace gave rise to the weight loss near 200 °C 
(Figure 2.7c).  Importantly, SMT-Acs had negligible weight loss below 150 °C, 
suggesting thermal stability acceptable for tablet development.
48 
2.3.3.3 Moisture Sorption Behavior 
Low hygroscopicity is preferred as the moisture content could alter the flowability, 
tabletability, and cause stability issue.
49-51
   The Acs free acid takes up nearly 30% 
of water when RH increased from 70% to 95% (Figure 2.8).  Thus, Acs is very 
hygroscopic according to the classification in the European Pharmacopeia.
52
  SMT is 
non-hygroscopic, since it only takes up negligible amount of water, 0.6%, at 95% RH.   
Moisture uptake by SMT-Acs, 0.2% at 95% RH, is the lowest, which also supports its 
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use in tablet manufacturing. 
2.3.3.4 Tabletability 
A tensile strength of 2 MPa is considered sufficient for maintaining tablet integrity 
during normal handling of most materials.
53
   The tabletability of SMT-Acs was 
significantly better than SMT (Figure 2.9a), where tensile strength of SMT-Acs tablets 
was approximately two times that of SMT tablet at a given pressure despite similar 
particle sizes (Figure 2.10).  Importantly, SMT-Acs tablet reached 2 MPa tensile 
strength at about 150 MPa, whereas SMT could not reach 2 MPa over the entire range 
of compaction pressure.  Thus, the improved tabletability of SMT-Acs also supports 
its use in tablet manufacturing. 
The higher tabletability can be attributed to either larger BA, higher BS, or both.
54, 55
  
To better understand the underlying mechanism of tabletability improvement, the 
plasticity of SMT and SMT-Acs was assessed, because more plastic materials can 
deform more easily to result in larger bonding area (BA).  SMT-Acs is more plastic 
than SMT, since both the Py and 1/C values of SMT-Acs were significantly lower than 
those of SMT (Table 2.4).  The greater plasticity explains the steeper decrease in 
tablet porosity of SMT-Acs with increasing pressure (Figure 2.9b).  It is interesting 
to note that tablet porosity of SMT-Acs was higher than that of SMT tablets at 
pressure < 300 MPa, despite the similar particle sizes (Figure 2.10).  Thus, the 
bonding area may not account for the higher tabletability of SMT-Acs despite its 
higher plasticity.  However, the tensile strength extrapolated to zero porosity, which 
 
 
25 
 
is a parameter for assessing the apparent bonding strength (BS), was comparable 
between SMT-Acs and SMT (Figure 2.9c).  Thus, BS cannot explain the superior 
tabletabilty of SMT-Acs.  Consequently, the larger BA is responsible for the better 
tabletability of SMT-Acs despite the larger tablet porosity below 300 MPa compaction 
pressures (Figure 2.9b).  This is possible only when the plasticity of SMT-Acs is 
significantly higher than SMT, which is supported by its significantly lower Py and 
1/C (Table 2.4).
55 
2.4 Structure-properties relationship 
The origin of the significantly greater plasticity of SMT-Acs than SMT can be 
understood by quantitatively examining their crystal structures using a computational 
tool kit.
56
  The most likely two-dimensional layers in SMT run along the ab plane 
(Figure 2.11a).  Neighboring molecules in this layer interact through N-H
…
O=S 
(2.947 Å) and N-H
…N (3.092 Å) hydrogen bonds as well as strong π-π interaction 
(3.393 Å) (Figure 2.11a).  Adjacent layers are fortified through weaker hydrogen 
bonds of C-H
…
O=S (3.331 Å) (Figure 2.11a).  The energy framework of SMT 
(Figure 11b) suggested that (0 0 1) planes exhibit higher intralayer bonding energy 
(-261.1 kJ/mol) than the interlayer bonding energy (-80.6 kJ/mol), which meets the 
anisotropic energy requirement for slip planes.  However, the molecular layers 
sliding along the (0 0 1) is hindered by the interdigitation between layers (negative 
interlayer distance of -1.80 Å) (Figure 2.11a).  
In comparison, the SMT-Acs exhibits a columnar structure running along the a axis 
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(Figure 2.11c). Within the columns, molecules are linked by N-H
…
N (2.796 Å), 
N-H
…
O (2.627 Å), and N-H
…
O=S (3.011 Å) hydrogen bonds.  Each column 
interacts with four neighboring columns via N-H
…
O=S (2.995 Å) hydrogen bonds 
(Figure 2.11c). The intracolumn bonding energy (-256.7 kJ/mol) is much higher than 
the intercolumn bonding energy (-92.8 kJ/mol) (Figure 2.11d), suggesting 
energetically favored molecular movement through slippage of columns, when the 
crystal is stressed.
6
  Both (0 1 2) and (0 0 1) are possible slip planes in SMT-Acs 
based on energy framework alone.  However, the (0 1 2) plane is likely the primary 
slip plane because of the lowest degree of interdigitation between adjacent layers 
(-0.22 Å) based on the topology analysis.  Therefore, the crystal structure of 
SMT-Acs supports its higher plasticity than SMT established by bulk powder 
compaction data (Table 2.4).
54 
 
2.5 Conclusions 
A sweet 1:1 salt between sulfamethazine and acesulfame was obtained.  
Characterization of solid-state and compaction properties suggests suitability of 
SMT-Acs for tablet formulation and manufacturing.  The better tabletability of 
SMT-Acs was attributed to its higher plasticity, which in turn is explained by the 
favorable crystal structure, featuring facile slip planes. 
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Table 2.1 Crystallographic data for the SMT-Acs crystal. 
Name SMT-Acs 
Formula C16H19N5O6S2 
Formula weight 441.48 
Temperature / K 100 (2) 
Crystal system Monoclinic 
Space group P21/n 
a, Å 8.3209 (2) 
b, Å 10.8674 (3) 
c, Å 21.7899 (5) 
a, deg 90 
b, deg 99.9810 (10) 
g, deg 90 
Volume, Å3 
1940.56 (8) 
Z 4 
Dc / g·cm
-3
 1.511 
F(000) 920 
GOF 1.085 
R1 [I>2sigma(I)] 0.0371 
wR2 [I>2sigma(I)] 0.0909 
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Table 2.2 Hydrogen bonds in SMT-Acs crystal. 
D-H...A D-H (Å) H..A (Å) D..A (Å) D-H...A (deg) Symmetry codes 
C1-H1C...O1 0.980 2.643 3.593 163.23 -x+1, -y+2, -z+1 
N3-H3A...N1 0.881 1.916 2.796 175.99  
N2-H2B...O5 0.884 2.334 2.995 131.56 -x+3/2, y-1/2, -z+3/2 
N2-H2A...O6 0.833 2.204 3.011 163.05 x+1, y, z 
N5-H5...O4 0.947 1.683 2.627 174.10  
C9-H9...O1 0.956 2.609 3.562 174.88  
C10-H10...O6 0.944 2.588 3.344 137.34 x+1, y, z 
C13-H13...O2 0.951 2.579 3.246 127.52 x, y-1, z 
C15'-H15D...O6 0.980 2.640 3.420 136.72 -x+1/2, y-1/2, -z+3/2 
C15'-H15E...O2 0.980 2.466 3.353 150.36 x, y-1, z 
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Table 2.3 Realistic interaction sites and corresponding ΔpKa in multicomponent 
crystals of SMT 
coformer SMT 
conformation 
SMT interaction 
site & pKa 
Coformer 
pKa 
ΔpKa 
2,4-dihydroxybenzoic 
acid 
amidine pyrimidine -N- 
(base), -0.97 
3.11 -4.08 
3,4-dichlorobenzoic acid amidine pyrimidine -N- 
(base), -0.97 
3.6 -4.57 
sorbic acid amidine pyrimidine -N- 
(base), -0.97 
4.76 -5.73 
1-hydroxy-2-naphthoic 
acid 
amidine pyrimidine -N- 
(base), -0.97 
10.94 -11.91 
benzene-1,2,4,5-tetracar
boxylic acid 
amidine pyrimidine -N- 
(base), -0.97 
1.87 -2.84 
2-hydroxybenzoic acid amidine pyrimidine -N- 
(base), -0.97 
2.97 -3.94 
2-nitrobenzoic acid amidine pyrimidine -N- 
(base), -0.97 
2.16 -3.13 
4-nitrobenzoic acid amidine pyrimidine -N- 
(base), -0.97 
3.41 -4.38 
2-aminobenzoic acid amidine pyrimidine -N- 
(base), -0.97 
2.14 -3.11 
4-aminobenzoic acid amidine pyrimidine -N- 
(base), -0.97 
2.38 -3.35 
1,4-diazabicyclo[2.2.2]o
ctane 
amidine sulfonamide 
-NH- (acid), 
6.99 
8.7 1.71 
acetylsalicylic acid amidine pyrimidine -N- 
(base), -0.97 
3.49 -4.46 
4-aminosalicylic acid amidine pyrimidine -N- 
(base), -0.97 
3.25 -4.22 
indole-2-carboxylic acid amidine pyrimidine -N- 
(base), -0.97 
4.44 -5.41 
2,4-dinitrobenzoic acid amidine pyrimidine -N- 
(base), -0.97 
1.43 -2.4 
4-chlorobenzoic acid amidine pyrimidine -N- 
(base), -0.97 
3.98 -4.95 
4,4'-ethane-1,2-diyldipyr
idine 
amidine pyrimidine -N- 
(base), -0.97 
6.13 7.1 
niflumic acid amidine pyrimidine -N- 
(base), -0.97 
1.88 -2.85 
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flufenamic acid amidine pyrimidine -N- 
(base), -0.97 
3.88 -4.85 
4-hydroxybenzoic acid imidine sulfonamide -N- 
(base), 7.01 
4.54 2.47 
benzamide imidine sulfonamide -N- 
(base), 7.01 
-2 -9.01 
picolinamide imidine sulfonamide -N- 
(base), 7.01 
-1.08 -8.09 
4-hydroxybenzamide imidine sulfonamide -N- 
(base), 7.01 
-3.01 -10.02 
3-hydroxy-2-naphthoic 
acid 
imidine sulfonamide -N- 
(base), 7.01 
2.79 4.22 
saccharine imidine sulfonamide -N- 
(base), 7.01 
1.31 5.7 
theophylline Amidine & 
imidine 
sulfonamide 
-NH- (acid), 
6.99 & 
sulfonamide -N- 
(base), 7.01 
7.82 (acid) 
&  -0.78 
(base) 
-0.81 & 
-7.77 
4-aminopyridine anion sulfonamide 
-NH- (acid), 
6.99 
8.95 1.96 
piperazine anion sulfonamide 
-NH- (acid), 
6.99 
9.56 2.57 
saccharin cation pyrimidine -N- 
(base), -0.97 
1.31 -2.28 
5-nitro-salicylic acid cation pyrimidine -N- 
(base), -0.97 
2.2 -3.17 
picric acid cation pyrimidine -N- 
(base), -0.97 
0.42 -1.39 
3,5-dinitrosalicylic cation pyrimidine -N- 
(base), -0.97 
1.53 -2.5 
acesulfame cation pyrimidine -N- 
(base), -0.97 
2 -2.97 
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Table 2.4 Plasticity parameters of SMT and SMT-Acs from in-die Heckel analysis 
and out-of-die KL analysis. 
 SMT SMT-Acs 
Py (MPa) 77.1 ± 1.2  (R
2
 = 0.99) 57.2 ± 3.3  (R
2
 = 0.98) 
1/C (MPa) 3345 ± 422  (R
2
 = 0.98)  818 ± 101  (R
2
 = 0.98) 
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Figure 2.1 Molecular structure of (a) sulfamethazine (b) acesulfame. 
 
 
 
 
 
 
 
 
(a) (b) 
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Figure 2.2 Crystal structure of SMT-Acs: (a) unit cell viewed along a-axis, (b) 
asymmetric unit, (c) SMT
+
 cations formed a chain along the b-axis, (d) 
three-dimensional packing diagram. 
 
 
 
 
(b) (a) 
(c) (d) 
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Figure 2.3 Ionization state distribution of SMT multicomponent crystals versus 
ΔpKa between interacting groups. Saccharin (blue line) forms both cocrystal and salt 
with SMT, while theophylline (orange line) forms cocrystal with amidine and 
imidine SMT simultaneously. 
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Figure 2.4 Bond length distributions of (a) C1-N2 vs. C1-N1 for SMT in crystal 
structures containing SMT, (b) C2-N3 vs. C2-O1 for Acs in known crystal structures 
containing Acs 
 
 
(a) 
(b) 
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Figure 2.5 IR spectra for SMT, Acs-K, and SMT-Acs. The 2636 cm
−1
 broad peak 
corresponds to NH
+
 stretching. 
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Figure 2.6 Calculated and experimental PXRD patterns of SMT-Acs 
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Figure 2.7 Thermal analysis of SMT, Acs, and SMT-Acs: (a) DSC, (b) HSM, and (c) 
TGA 
 
 
 
(a) 
(c) 
(b) 
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Figure 2.8 Moisture sorption curves of SMT, Acs and SMT-Acs. 
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Figure 2.9 (a) Tabletability (b) compressibility, and (c) compactability profiles of 
SMT and SMT-Acs, where the shaded bands indicate 90% confidence interval. 
 
 
 
 
(a) (b) 
(c) 
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Figure 2.10 Particle size of (a) SMT and (b) SMT-Acs. 
 
 
 
 
(b) 
(a) 
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Figure 2.11 Crystal packing patterns (left) and corresponding energy framework 
(right) for SMT (a, b) and SMT-Acs salt (c, d) viewed along c axis. The thickness of 
each cylinder (in blue) represents the relative strength of interaction. 
 
 
 
 
(b) 
(c) (d) 
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CHAPTER 3. 
 
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ 
 
RESEARCH SUMMARY AND FUTURE WORK 
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Research Summary 
A sweet 1:1 salt between sulfamethazine and acesulfame, SMT-Acs, was successfully 
prepared and characterized.  The solid-state and compaction properties of SMT-Acs 
suggests its suitability for tablet formulation and manufacturing.  The better 
tabletability of SMT-Acs was attributed to its higher plasticity, which in turn is 
explained by the presence of facile slip planes in the crystal structure that favors 
plastic deformation. 
Future Work 
The thermal behavior of SMT-Acs captured by DSC and HSM are consistent.  We 
also demonstrated the thermal stability of SMT-Acs from the TGA data.  However, 
the nature of the thermal events between 190 and 200 °C remains elusive.  Thus, 
further investigations are needed to fully understand the thermal properties of 
SMT-Acs.  DSC experiments at different heating rates and variable temperature 
XRD may be of help to elucidate these observations.  In addition, additional 
confirmation of the sweetness of SMT-Acs by either a taste panel or E – tongue test is 
needed.  
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